CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC (QUATTRO-II)

Chugai Pharmaceutical

Status and phase: Unknown; Phase 2

Conditions: Metastatic Colorectal Cancer

Treatments: Drug: Irinotecan hydrochloride; Drug: Leucovorin calcium; Drug: 5-fluorouracil; Drug: Capecitabine; Biological: Bevacizumab; Drug: Oxaliplatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT04097444

QUATTRO-II

Details and patient eligibility

About

The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer (mCRC).

Full description

QUATTRO-II is an open-label, multicenter, randomised, phase II study to investigate the efficacy and safety of CAPOXIRI+BEV versus FOLFOXIRI+BEV in 1st line mCRC.

This study is composed two steps because of confirming of recommended dose (RD) for CAPOXIRI+BEV regimen.

1. Dose finding step (Step1): CAPOXIRI+BEV doses findings were planned by 3+3 cohort design, register up to maximum of 12 cases.
2. Randomised step (Step2): After confirmation of RD regarding CAPOXIRI+BEV, we will move to Step2 to compare the efficacy and safety between FOLFOXIRI+BEV and CAPOXIRI+BEV, register up to 65 cases.

Enrollment: 112 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Personal written informed consent is obtained after the study has been fully explained

2. Histologically confirmed colon or rectal adenocarcinoma

   *Excluding appendix cancer and anal canal cancer

3. Clinically unresectable

4. ≥20 years of age at enrollment

5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1 (≥71 years of age: PS score of 0)

6. Measurable lesion according to RECIST ver. 1.1 criteria on contrast-enhanced chest, abdominal, or pelvic (trunk) CT (required within 28 days of enrollment)

7. No previous chemotherapy for colon or rectal cancer

   *Patients with confirmed relapse ≥24 weeks after completion of post-operative adjuvant chemotherapy can be enrolled

8. Ras/Braf mutation analysis at enrollment identifies Ras/Braf status as either the wild type or mutant type.

9. Vital organ functions meet the following criteria within 14 days before enrollment.

   If multiple test results are available in that period, the results closest to enrollment will be used. No blood transfusions or hematopoietic factor administration will be permitted within 2 weeks before the date on which measurements are taken.

   i. Neutrophil count: ≥1,500 /cu.mm

   ii. Platelet count: ≥10.0 × 104/cu.mm

   iii. Hemoglobin concentration: ≥9.0 g/dL

   iv. Total bilirubin: ≤1.5 times upper limit of normal (ULN)

   v. Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP): ≤2.5 times ULN (≤5 times ULN for metastases to liver)

   vi. Serum creatinine: ≤1.5 times ULN, or creatinine clearance: ≥30 mL/min

   vii. Urine protein: ≤2+ (if ≥3+, urine protein/creatinine ratio: <2.0)

10. UGT1A1 polymorphism is wild type or single heterozygous type -

Exclusion criteria

1. Previous radiation therapy in which ≥20% bone marrow was exposed to the radiation field

2. Untreated brain metastases, spinal cord compression, or primary brain tumor

3. History of central nervous system (CNS) disease (excluding asymptomatic lacunar infarction)

4. Continuous systemic corticosteroid treatment is required

5. Oral or parenteral (such as low molecular weight heparin) anticoagulant dose is not consistently (≥14 days) controlled. (Oral anticoagulants: conditions at high risk for bleeding, such as prothrombin time (PT)-international normalized ratio (INR) ≥3, clinically significant active bleeding (within 14 days of enrollment))

6. Evidence of cardiovascular disease, cerebrovascular disorder (within 24 weeks), myocardial infarction (within 24 weeks), unstable angina pectoris, New York Heart Association (NYHA) classification ≥Grade II congestive heart failure, serious arrhythmias requiring drug therapy

7. Previous treatment with an investigational drug within 28 days prior to enrollment, or participation in a study of an unapproved drug

8. Any of the following comorbidities

   i. Uncontrolled hypertension

   ii. Uncontrolled diabetes mellitus

   iii. Uncontrolled diarrhea

   iv. Peripheral sensory neuropathy (≥Grade 1)

   v. Active peptic ulcer

   vi. Unhealed wound (except for suturing associated with implanted port placement)

   vii. Other clinically significant disease (such as interstitial pneumonia or renal impairment)

9. Major surgical procedure within 28 days prior to study treatment initiation (such as open chest, laparoscopy, thoracoscopic surgery, laparoscopic surgery), unless only colostomy is performed; open biopsy or suturing for major trauma within 14 days of study treatment initiation; or planned major surgical procedure during the study (open chest, laparoscopy) ("major surgical procedures" does not include central venous (CV) port insertion)

10. Physical defects of the upper gastrointestinal tract; malabsorption syndrome or difficulty taking oral medication

11. Pregnant, breastfeeding, positive pregnancy test (women who have menstruated in the last year will be tested), or women who are unwilling to use contraception; men who are unwilling to use contraception during the study

12. Active hepatitis B or C, or evidence of HIV infection

13. Previous chemotherapy for other malignancies (excluding hormone therapy for breast cancer)

14. Other active malignancies (synchronous malignancies, and asynchronous malignancies separated by a 5-year disease-free interval) (excluding malignancies that are expected to be completely cured, such as intramucosal carcinoma and carcinoma in situ)

15. Uncontrolled venous thromboembolism (unless clinically stable, asymptomatic, or appropriately treated with an anticoagulant)

16. Arterial thrombosis or arterial thromboembolism such as myocardial infarction, transient ischemic attack, or cerebrovascular attack in the last year prior to enrollment

17. Complications such as intestinal paralysis, intestinal obstruction, or gastrointestinal perforation, current or within 1 year prior to enrollment

18. Pleural effusion, ascites, or pericardial effusion requiring drainage

19. History of hypersensitivity to fluorouracil, levofolinate, oxaliplatin, irinotecan, bevacizumab and their excipients or Chinese hamster ovary cell proteins

20. History of adverse reactions to fluoropyrimidine drugs indicative of dihydropyrimidine dehydrogenase (DPD) deficiency

21. Systemic treatment required for, or evidence of, infections

22. Endoluminal stenting

23. Otherwise unsuitable for the study in the opinion of investigators -

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

112 participants in 3 patient groups

Step 1 (CAPOXIRI+ BEV)

Experimental group

Description:

Induction therapy is followed by the maintenance therapy. \[Induction treatment: CAPOXIRI+BEV\] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) oxaliplatin (OX): 100/130 mg/sq.m (d.i.v.) irinotecan (IRI):150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. OX/IRI dose is applied according to the progress of Step 1. \[Maintenance treatment: 5-fluorouracil (FU)/Levofolinate calcium (LV)+BEV or CAP+BEV\] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV). 5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks. CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks.

Treatment:

Drug: Oxaliplatin

Biological: Bevacizumab

Drug: Capecitabine

Drug: Irinotecan hydrochloride

Step 2 Arm A (FOLFOXIRI+ BEV)

Experimental group

Description:

Induction therapy is followed by the maintenance therapy. \[Induction treatment: FOLFOXIRI+BEV\] Administered for 8 cycles (a maximum of 12 cycles). BEV: 5mg/kg (d.i.v.) OX: 85 mg/sq.m (d.i.v.) IRI:165mg/sq.m (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks. \[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV\] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV). 5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks. CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. Day1-15) Administered every 3 weeks.

Treatment:

Drug: Oxaliplatin

Biological: Bevacizumab

Drug: 5-fluorouracil

Drug: Leucovorin calcium

Drug: Irinotecan hydrochloride

Step 2 Arm B (CAPOXIRI+ BEV)

Experimental group

Description:

Induction therapy is followed by the maintenance therapy. \[Induction treatment: CAPOXIRI+BEV\] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) OX: 100/130 mg/sq.m (d.i.v.) IRI:150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. Regarding to OX/IRI dose, RD will be confirmed at Step 1. \[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV\] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV). 5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks. CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks.

Treatment:

Drug: Oxaliplatin

Biological: Bevacizumab

Drug: Capecitabine

Drug: Irinotecan hydrochloride